ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway
Oncology Research and Treatment · 2021 · 44 (1-2) · 20-27
DOI: 10.1159/000511919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 04.12.2020. Verfasst von Oded Jacobi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel, jacobi.oded@gmail.com. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background/Aims: Current chemotherapy regimens for cholangiocarcinoma (CCA) yield poor outcomes, with a median overall survival of <12 months. Recent data on the genomic landscape of CCAs have created opportunities for targeted therapy. Yet, data regarding its efficacy are scarce. We aimed to describe the genomic landscape of a CCA patient cohort using next-generation sequencing (NGS), focusing on the ERBB/EFGR pathway and assessing response to anti-HER2 agents.
Methods
Tissue samples of intrahepatic CCA (IHCC) and extrahepatic CCA (EHCC) underwent NGS for somatic aberrations. The clinical outcomes for patients treated with anti-HER2 agents were evaluated.
Results
A total of 1,863 CCA cases (1,615 IHCCs and 248 EHCCs) underwent NGS, and they revealed a high prevalence of ERBB alterations (IHCC, 4.2%; EHCC, 9.7%). Among these, 23.8% of the IHCCs and 53.6% of the EHCCs had a point mutation in ERBB2, and 66.6% of the IHCCs and 41.2% of the EHCCs had ERBB copy number amplification. Three EHCC patients were diagnosed at our institute with ERBB/EGFR aberrations; 2 patients were treated with neratinib and 1 patient with a chemotherapy-trastuzumab combination. All 3 achieved disease stabilization and a clinical benefit. One patient underwent a liquid biopsy before and after 3 months of treatment, demonstrating disappearance of the ERBB2 clone and emergence of a Myc-mutated clone after treatment.
Conclusions
The genomic landscape of CCAs may harbor targetable alterations, especially in the ERBB/EGFR pathway. These alterations may have clinical significance in everyday practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel, jacobi.oded@gmail.com.
- Foundation Medicine Inc., Cambridge, Massachusetts, USA.
- Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel.
- Department of Surgery, Carmel Medical Center, Haifa, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Zitieren
APA
Jacobi, O., Ross, J. S., Goshen-Lago, T., Haddad, R., Moore, A., Sulkes, A., Brenner, B., & Ben-Aharon, I. (2021). ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncology Research and Treatment, 44(1-2), 20-27. https://doi.org/10.1159/000511919
Vancouver
Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, et al. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncology Research and Treatment. 2021;44(1-2):20-27. doi:10.1159/000511919
BibTeX
@article{Jacobi2021,
author = {Jacobi, Oded and Ross, Jeffrey S and Goshen-Lago, Tal and Haddad, Riad and Moore, Assaf and Sulkes, Aaron and Brenner, Baruch and Ben-Aharon, Irit},
title = {ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway},
journal = {Oncology Research and Treatment},
year = {2021},
volume = {44},
number = {1-2},
pages = {20--27},
doi = {10.1159/000511919}
}
EUVIMED